This clinical review sets out how to spot and treat iron deficiency in girls and women, drawing on trials, observational studies and guidelines. It reports that a Canadian screening study found 38% of non-pregnant females had iron deficiency without anemia and 13% had iron deficiency anemia. The authors set ferritin thresholds for starting treatment, put oral iron salts first, and reserve intravenous iron for malabsorption, intolerance or severe anemia.
Iron deficiency means the body's iron stores are low. Iron deficiency anemia means those low stores have started limiting red blood cell production. Both cause harm, and the version without anemia is often missed because a standard blood count looks normal. Females carry most of the burden, through menstrual blood loss, pregnancy and the postpartum period. Canadian hematologists and laboratory physicians wrote this review to set out how iron deficiency should be diagnosed and treated.
This is a narrative clinical review, not new research. The authors searched PubMed from inception to February 2024 for trials, observational studies and systematic reviews on iron deficiency with and without anemia, and reviewed guidelines and consensus recommendations. It was peer reviewed. There are no participants and no new data: every figure comes from other studies.
The review reports figures from the studies it cites.
This is a narrative review rather than a systematic one, so the search is not reproducible and no quality assessment or pooled estimate is given. Figures come from single cohorts and surveys, several from Ontario, and the observational links with mortality and pregnancy outcomes cannot establish cause. Guidance is not settled: the review suggests testing every three years for females of reproductive age, which the authors call reasonable given unaligned guidelines, while the 2024 US Preventive Services Task Force found insufficient evidence to recommend for or against screening in pregnancy. Three of the four authors declare payments from pharmaceutical companies. Michelle Sholzberg reports research funding from Pfizer and Octapharma and honoraria from Octapharma, Sobi, Werfen and Roche. Christopher Hillis reports honoraria from AstraZeneca, Janssen, Novartis and Beigene. Mark Crowther reports consulting fees from CSL Behring and Eversana, honoraria from Pfizer and AstraZeneca, and expert testimony payment from Bayer.
This is clinical guidance for doctors on diagnosing and treating a medical condition. Its most useful point for a general reader is diagnostic: a normal blood count does not rule out iron deficiency, ferritin reflects iron stores, and the Canadian threshold was recently raised. It evaluates no supplement product, and says plainly that diet alone cannot treat deficiency in menstruating or pregnant people. The oral iron discussed is treatment dosing of 35 to 100 mg elemental iron, alongside investigation of why iron is being lost. The review is about people who are iron deficient or anemic, not healthy people with normal stores, and nothing in it supports taking iron without testing first.
That depends on the specific medication and formula. A few, like blood thinners with CurQLife or blood pressure medication with MaxiNOs, are worth a direct conversation with your doctor first. Check each formula's own FAQ section for specifics, or ask your health coach.
No, and we'd rather be upfront about it. Bacopa, the plant in BacoZest, has published human studies, though they used other bacopa extracts. OptiNOs and MaxiNOs each have human studies sponsored by their maker, Laila Nutraceuticals, which haven't been published in a journal. CurQLife's research is still early, from lab and animal studies, and we label it that way.
It depends on what you're building your routine around. BacoZest is built around bacopa, which is studied for memory.* OptiNOs supports strength and muscular endurance alongside resistance training.* MaxiNOs was studied for healthy blood vessel function.* CurQLife's research is still at the lab stage. Your health coach can help you pick a starting point.
All four are built around plant extracts. OptiNOs was reported as well tolerated in its human study, and published bacopa studies reported no serious side effects. CurQLife's safety data so far comes from lab and animal testing. Check with your doctor first if you're pregnant, nursing, on medication, or managing a health condition.
Because the patented ingredients behind our four formulas went through dedicated research, and research costs real money. A generic curcumin or bacopa supplement hasn't been tested in the form you get from us. You're paying for an ingredient with research behind it, not just a label.
Generic ingredients often haven't been studied in the specific form you're buying. Our four core formulas use patented ingredients, and we show you the research behind each one, including where it's still early.
It depends on the formula. In its study, MaxiNOs blood vessel response was higher than placebo 2 to 3 hours after the first dose.* OptiNOs and bacopa were studied over 6 and 12 weeks of daily use, so give them time. CurQLife is meant to be taken daily.
Yes. BacoZest, OptiNOs, MaxiNOs, and CurQLife are built for different goals, and none of them contain stimulants. They haven't been studied together, so ask your health coach how to fit them into your routine.
